Search Within

James Joseph Harding

Formats
  1. Meeting Abstract (124)
  2. Journal Article (115)
  3. Review (7)
  4. Book Section (3)
  5. Miscellaneous (3)
Groups
  1. Department of Medicine (252)
  2. Gastrointestinal Oncology Service (252)
  3. Solid Tumor Oncology Division (252)
  4. Center for Pancreatic Cancer Research (129)
  5. GSK Faculty (99)
  6. Epidemiology and Biostatistics (89)

More Groups

People
  1. Ghassan Abou-Alfa (130)
  2. Eileen O'Reilly (70)
  3. William Jarnagin (59)
  4. Michael D'Angelica (40)
  5. Andrea Cercek Hanjis (38)
  6. Michael Berger (37)

More People

Years
  1. 2025 (13)
  2. 2024 (32)
  3. 2023 (34)
  4. 2022 (21)
  5. 2021 (23)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Annals of Oncology (17)
  3. Clinical Cancer Research (15)
  4. Annals of Surgical Oncology (13)
  5. Cancer (9)
  6. JCO Precision Oncology (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (99)
  2. Oxford University Press (25)
  3. American Association for Cancer Research (23)
  4. Springer (20)
  5. Wiley Blackwell (14)
  6. Elsevier Science, Inc. (10)

More Publishers

Results (252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing
    Meeting Abstract

    McIntyre, S. M.; Preston, W.; Walch, H.; Sigel, C.; Sharib, J.; Chen, W.; Lidsky, M. E.; Kundra, R.; Cercek, A.; Harding, J. J.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage
    Meeting Abstract

    Sharib, J.; Liu, A.; McIntyre, S.; Rhodin, K. E.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; Abou-Alfa, G. K.; Soares, K. C.; Wei, A. C.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C.; Schultz, N.; Walch, H.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Meeting Abstract

    Harding, J.; Ikeda, M.; Goyal, L.; Rodon, J.; Bai, L.; Oh, D.; Park, J.; Chen, L.; Ueno, M.; Liao, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Meeting Abstract

    Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Meeting Abstract

    Harding, J.; Perez, C.; Kato, S.; Sharma, M.; Garmezy, B.; Quah, C.; Tam, B.; Severson, P.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
    Meeting Abstract

    Macarulla, T.; Harding, J.; Morizane, C.; Ohkawa, K.; Ueno, M.; Vogel, A.; Lamarca, A.; Yamamoto, N.; Javle, M.; Hu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2
    Meeting Abstract

    Goyal, L.; Harding, J. J.; Ueno, M.; Lamarca, A.; Macarulla, T.; Yamamoto, N.; Hu, J.; Teufel, M.; Maerten, A.; Vogel, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
    Meeting Abstract

    Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla Mercade, T.; Xie, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save